BMY bms.com: Quick Liquidity Indicator

The critical liquidity ratio demonstrates the solvency of Bristol-Myers Squibb (BMY), where the 1.41 metric determines this level. The holding is exposed to supply chain disruption risks and complexities of foreign patent law. Exclusive rights to oncology drugs allow the company to maintain high pricing power, while portfolio renewal replaces legacy products with new therapies.

BMS (BMY) - Intermediate Coverage Ratio from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for bms.com (BMY)

- share price and expert price forecast:

Stock Price BMS|BMY - Analyst Consensus Forecast

- company stock capitalization data:

Market Valuation BMS|BMY - Value Adjusted for Debt and Cash

- book capitalization indicators:

Book Value per Share Bristol Myers Squibb|BMY - Accounting Value of Company|Market Value to Book Value Ratio bms.com|BMY - Company Assets

- business debt structure and liquidity details:

- earnings and valuation multiples indicators:

BMY - Annual Net Income

Summary company analysis:BMS - BMY

Stable demand for Bristol-Myers Squibb (BMY) drugs makes the quick ratio a reliable indicator of the business's resilience to external shocks. This metric determines the company's ability to instantly settle short-term obligations without liquidating inventory. The calculation is based on the ratio of cash and accounts receivable to current liabilities. High values confirm excess liquidity, guaranteeing financial security with minimal default risks.

Competitors of Bristol-Myers Squibb (BMY)